RLD strength for BE study [Design Issues]

posted by Brus – Spain, 2021-01-21 15:24 (1240 d 00:42 ago) – Posting: # 22186
Views: 2,271

Dear Colleagues,

We are developing a generic of an RLD with two strengths (100 mg and 50 mg).

But viewing the dosage regimen of reference drug product, it would make sense to develop a 150 mg strength even though the reference product does not have it. So, our generic drug product will have 3 strengths (150, 100 and 50 mg).

What dose should the BE study be done with? (PK linearity has been demonstrated in the range of that doses).

Should RLD 100mg VS Generic 100mg be done or RLD 100mg + RLD 50mg VS generic 150mg?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,056 posts in 4,840 threads, 1,641 registered users;
136 visitors (0 registered, 136 guests [including 67 identified bots]).
Forum time: 17:07 CEST (Europe/Vienna)

Exploratory analysis: The art of finding a Rembrandt
in a Jackson Pollock.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5